kez.biosolutions

kez.biosolutions is an early-stage biotech leveraging synthetic biology to revolutionize polyketide engineering. Its kezbio platform utilizes proprietary enzyme technology and substrates to precisely modify polyketide scaffolds, aiming to generate novel drug candidates against resistant pathogens and for other therapeutic applications. Currently in a proof-of-concept phase with an erythromycin-based library, the company plans to offer customized strain and substrate packages to partners. It operates as a pre-revenue, private entity focused on platform development and future collaborative R&D.

The kezbio platform utilizes proprietary KEZ® substrates and the Selectase® enzyme to enable precise, site-specific incorporation of novel chemical functions into polyketide scaffolds during biosynthesis in microbial bioreactors, creating new-to-nature molecules.

Competition includes other synthetic biology companies engineering natural product pathways (e.g., Antheia, Demetrix, Synlogic) and large pharmaceutical firms with internal natural product discovery units. The company's differentiation lies in its specific focus on precise, enzymatic polyketide backbone modification using its proprietary Selectase® enzyme and substrate system.